Caisse DE Depot ET Placement DU Quebec Boosts Stock Position in Danaher Corporation $DHR

Key Points

• The Caisse DE Depot ET Placement DU Quebec increased its holdings in Danaher Corporation by 34.6% during the 1st quarter, owning 670,926 shares valued at approximately $137.54 million.
• In its latest earnings report, Danaher reported an EPS of $1.80, surpassing analyst expectations of $1.64, with a revenue of $5.94 billion.
• Seventeen analysts have rated Danaher stock with a "Buy" rating, leading to a consensus rating of "Moderate Buy" and an average price target of $247.61.

Caisse DE Depot ET Placement DU Quebec lifted its position in Danaher Corporation (NYSE:DHR - Free Report) by 34.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 670,926 shares of the conglomerate's stock after acquiring an additional 172,451 shares during the period. Caisse DE Depot ET Placement DU Quebec owned 0.09% of Danaher worth $137,540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Soros Capital Management LLC boosted its stake in shares of Danaher by 288.1% in the first quarter. Soros Capital Management LLC now owns 12,991 shares of the conglomerate's stock worth $2,663,000 after acquiring an additional 9,644 shares during the last quarter. Full Sail Capital LLC boosted its stake in shares of Danaher by 9.2% in the first quarter. Full Sail Capital LLC now owns 2,980 shares of the conglomerate's stock worth $611,000 after acquiring an additional 250 shares during the last quarter. Ally Financial Inc. grew its stake in Danaher by 66.7% during the 1st quarter. Ally Financial Inc. now owns 25,000 shares of the conglomerate's stock valued at $5,125,000 after acquiring an additional 10,000 shares in the last quarter. Thematics Asset Management raised its holdings in Danaher by 2.5% in the 1st quarter. Thematics Asset Management now owns 75,301 shares of the conglomerate's stock valued at $15,437,000 after acquiring an additional 1,805 shares during the last quarter. Finally, ICONIQ Capital LLC raised its holdings in Danaher by 86.1% in the 1st quarter. ICONIQ Capital LLC now owns 2,134 shares of the conglomerate's stock valued at $437,000 after acquiring an additional 987 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Up 0.2%

NYSE:DHR traded up $0.42 on Thursday, reaching $205.42. The company's stock had a trading volume of 2,519,853 shares, compared to its average volume of 3,496,339. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm has a market cap of $147.09 billion, a price-to-earnings ratio of 43.71, a price-to-earnings-growth ratio of 2.86 and a beta of 0.73. The stock has a 50 day moving average price of $201.23 and a 200 day moving average price of $199.46.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the previous year, the business earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of analyst reports. Barclays restated an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Wells Fargo & Company reduced their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. Finally, Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.